On June 15, 2025 MonTa Biosciences reporteed it has been granted a key U.S. patent covering our lead cancer immunotherapy candidate, MBS8 (Press release, MonTa Biosciences, JUN 15, 2025, View Source [SID1234654221]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This newly issued patent provides broad protection for MBS8 and its use in the treatment of cancer, securing our position in the most important global pharmaceutical market. The granted claims cover the unique micellar formulation of our TLR7 agonist as well as its therapeutic application, ensuring strong exclusivity for the development and commercialization of MBS8 in the U.S.

MBS8 is designed to stimulate the innate immune system to combat cancer and is currently advancing through clinical development. With this U.S. patent, MonTa takes a major step forward in protecting the future treatment potential of MBS8 for cancer patients.

This milestone reinforces our strategy to build a robust global IP portfolio around MBS8 as we continue our mission to deliver breakthrough immunotherapies that not only extend life — but aim to cure.